«There is a revolution taking place in the
practice of
medicine, particularly cancer therapy, and most of that innovation is taking place in the biotech
companies,» said Chris Sassouni, health care specialist and co-portfolio manager of the mid-cap growth investment team at Eagle Asset
Management.